Abstract
One way to address the current crisis in opioid use is to improve our understanding of the biological mechanisms of opioid use disorder (OUD). We completed a primary GWAS of electronic health record-defined OUD in European-ancestry participants in the Million Veteran Program (MVP) sample, which included 8,529 affected subjects and 71,200 opioid-exposed controls. In the MVP alone, there were no genome-wide significant (GWS) associations. We then subjected the MVP and additional OUD GWAS results from the Yale-Penn and SAGE samples to meta-analysis (in total, 10,544 OUD cases and 72,163 opioid-exposed controls). A functional coding variant (rs1799971, encoding Asn40Asp) in OPRM1 (mu opioid receptor gene, the main biological target for opioid drugs) reached GWS (p=1.51×10−8); then replicated in two independent samples (each at p<0.05). The final meta-analyzed p-value for this variant in all samples was 7.81×10−10. SNP-based heritability of OUD was 11.3%. OUD was genetically correlated with 83 traits, including multiple substance use traits, psychiatric illnesses, cognitive performance, and others. Mendelian Randomization revealed possible causal effects on OUD risk from tobacco smoking, major depression, neuroticism, and cognitive performance. Despite the inclusion of data from the MVP, discovery of a significant association depended on including other purpose-collected samples as well. Recruitment of additional opioid dependent subjects for future studies – especially of non-European ancestry – is a crucial next step.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research used data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #1I01BX003341. This publication does not represent the views of the Department of Veterans Affairs or the United States Government. Supported also by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (HZ). Dr. Gelernter was supported by National Institutes of Health grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, and R01 AA017535, the New England MIRECC, and by the Department of Veterans Affairs Medical Research Program. Dr. Kranzler was supported by National Institutes of Health grants R21 DA10242 and R01 DA18432 and both he and Dr. Kember were supported by the VISN 4 MIRECC. Genotyping services for a part of the Yale-Penn GWAS study were provided by the Center for Inherited Disease Research (CIDR) and Yale University (Center for Genome Analysis). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University (contract number N01-HG-65403). The publicly available dataset of Study of Addiction: Genetics and Environment (SAGE) used for the analysis was obtained from dbGaP at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000092.v1.p1. Funding support for SAGE was provided through the NIH (U01 HG004422). SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies (GENEVA) under Genes, Environment and Health Initiative (GEI). Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
The summary statistics will be available after publication.
